Results 241 to 250 of about 1,732,290 (301)

Targeting the PHB2–ACSL3 Lipid‐Remodeling Axis Overcomes Cisplatin Resistance by Restoring Ferroptosis in Gastric Cancer

open access: yesAdvanced Science, EarlyView.
ABSTRACT Platinum‐based chemotherapy resistance remains a major obstacle in gastric cancer (GC) treatment. Through integrated transcriptomic profiling of cisplatin‐resistant xenografts and pharmacogenomic interrogation of the NCI‐60 dataset, we identified Prohibitin‐2 (PHB2) as a previously unrecognized determinant of chemoresistance.
Liang Xu   +10 more
wiley   +1 more source

Tissue‐Agnostic Cellular Morphometric Biomarkers for Risk‐Adapted Management Across Gastrointestinal Precancerous Lesions and Cancers

open access: yesAdvanced Science, EarlyView.
An interpretable, unsupervised artificial intelligence framework identifies a 13‐cellular morphometric biomarker (CMB) signature from routine H&E whole‐slide images. Validated across 2,602 patients, the fixed signature generalizes across colorectal, gastric, and esophageal tissues without retraining, stratifies prognosis and precancerous lesion risk ...
Pin Wang   +14 more
wiley   +1 more source

Determinants of synchronous and metachronous metastatic breast cancer (2000-2024)-an analysis based on data from German cancer registries. [PDF]

open access: yesJ Cancer Res Clin Oncol
Lacruz ME   +14 more
europepmc   +1 more source

Clinical case giant malignant phyllodes tumor of the breast. [PDF]

open access: yesJ Surg Case Rep
Amaya AHS   +4 more
europepmc   +1 more source

Hematologic breast malignancies: a single-institution cohort study of 24 patients diagnosed between January 2008 and June 2023, with clinicopathological and outcome analysis. [PDF]

open access: yesFront Oncol
Navarro L   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy